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Abstract
EGFR-signalling inhibition by monoclonal antibodies (MAb) and EGFR-speciﬁc 
tyrosine kinase inhibitors has shown clinical efﬁcacy in cancer by restoring 
susceptibility of tumour cells to therapeutic apoptosis induction. TRAIL is a 
promising anti-cancer agent with tumour-selective apoptotic activity. Here we 
present a novel approach that combines EGFR-signalling inhibition with target 
cell-restricted apoptosis induction using a TRAIL fusion protein with engineered 
speciﬁcity for EGFR. This fusion protein, scFv425:sTRAIL, comprises the EGFR-
blocking antibody fragment scFv425 genetically fused to soluble TRAIL (sTRAIL). 
Treatment with scFv425:sTRAIL resulted in the speciﬁc accretion to the cell 
surface of EGFR-positive cells only. EGFR-speciﬁc binding rapidly induced the 
dephosphorylation of EGFR- and downstream mitogenic signalling, which was 
accompanied by c-FLIPL down-regulation and BAD dephosphorylation. EGFR-
speciﬁc binding converted soluble scFv425:sTRAIL into a membrane-bound 
form of TRAIL that crosslinked agonistic TRAIL receptors in a paracrine manner, 
resulting in potent apoptosis induction in a series of EGFR-positive tumour cell 
lines. Co-treatment of EGFR-positive tumour cells with the EGFR tyrosine kinase 
inhibitor Iressa resulted in a potent synergistic pro-apoptotic effect, caused 
by the speciﬁc down-regulation of c-FLIPL. Furthermore, in mixed culture 
experiments binding of scFv425:sTRAIL to EGFR-positive target cells conveyed 
a potent apoptotic effect towards EGFR-negative bystander tumour cells. The 
favourable characteristics of scFv425:sTRAIL, alone and in combination with 
Iressa, as well as its potent anti-tumour bystander activity indicate its potential 
value for treatment of EGFR-expressing cancers.
 
Introduction
The Epidermal Growth Factor Receptor (EGFR) is a transmembrane receptor tyrosine 
kinase comprising an extra-cellular ligand binding domain, a transmembrane lipophilic 
segment, and an intra-cellular tyrosine kinase domain1,2. Binding of its ligand EGF or TGFα 
results in EGFR-dimerization and activates the intrinsic protein tyrosine kinase. Activated 
EGFR concomitantly triggers signalling by the downstream mitogenic signal transduction 
pathways p44/42 MAPK and PI3K3,4. 
Normal EGFR signalling plays a pivotal role in organ development and repair. The important 
role of EGFR in the regulation of cell survival is underscored by the fact that aberrant 
EGFR activity strongly contributes to tumorigenesis in various tumour types. Aberrant 
activation of EGFR is associated with reduced recurrence-free or overall survival rates5,6 
and can arise from EGFR gene ampliﬁcation, leading to high cell surface expression of 









of the most frequent tumour speciﬁc mutant forms is the EGFRvIII, a mutant receptor 
commonly found in glioblastoma multiforma7,8. EGFRvIII possesses ligand-independent 
tyrosine kinase activity9 and is associated with enhanced tumorigenicity in mice10,11. Very 
recently, mutations have been identiﬁed in the intra-cellular tyrosine kinase domain of 
EGFR in lung cancer patients that appear to activate anti-apoptotic pathways.
Several strategies have been developed to speciﬁcally inhibit aberrant EGFR signalling. 
Monoclonal antibodies, e.g. MAb C225 (CetuximabTM) and MAb 42512,13, competitively 
inhibit the binding of natural ligands to the extracellular ligand-binding domain. Small 
molecule tyrosine kinase inhibitors, e.g Iressa (ZD1839 or GeﬁtinibTM)14,15, competitively 
inhibit with ATP for binding to the intracellular tyrosine kinase domain. The clinical efﬁcacy 
of these agents appears to rely on multiple anti-cancer mechanisms, including inhibition 
of cell cycle progression, inhibition of metastasis, and an increase in the susceptibility of 
cells to apoptosis. 
However, despite promising anti-tumour activity in clinical trials16-19, both classes of 
EGFR-signalling antagonists do not appear to be curative. Therefore, additional EGFR-
targeted strategies or combination with other therapeutic approaches are warranted. In 
this respect, strong synergistic tumoricidal effects have been reported for strategies in 
which EGFR-signalling antagonists are combined with radiation- or chemotherapy17,19,20, 
and more recently, with the cytokine TRAIL21.
TRAIL is normally present as a trimeric type II transmembrane protein (memTRAIL) on 
various immune effector cells. TRAIL speciﬁcally induces apoptosis in cancer cells22 and 
virus-infected cells23, without apparent apoptotic activity towards normal human cells. 
Homotrimeric memTRAIL initiates apoptosis by crosslinking of the agonistic receptors 
TRAIL-R1 and TRAIL–R224-27, leading to activation of the extrinsic apoptotic pathway via 
the Death Inducing Signalling Complex (DISC)28-35. Assembly of the DISC sequentially 
activates initiator caspases (caspase-8 or -10) and effector caspases (e.g. caspase-3, and 
-7) and ultimately ends in apoptotic cell death. 
MemTRAIL can be proteolytically cleaved into a soluble form (sTRAIL). Several recombinant 
forms of sTRAIL have been generated that show strong tumoricidal activity in vitro and 
in xenografted mouse models without toxic side-effects36-38. Pharmacokinetic studies in 
cynamolgous monkeys and chimpanzees revealed no toxicity, thus further establishing 
the potential for clinical application of sTRAIL in cancer therapy. 
However, TRAIL receptors are expressed in various tissues and, thereby, may potentially 
compete with tumour tissue for binding of i.v. applied sTRAIL. In addition, several papers 
described apoptotic activity of sTRAIL on various normal cells, including primary human 
hepatocytes39, keratinocytes40, prostate epithelial cells41 and brain tissue42. Fortunately, 
the binding characteristics of sTRAIL for its receptors have typical “fast on/fast off” rates. 
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speciﬁc antibody fragment with “fast on/slow off” rates43,44, resulting in the preferential 
binding to the pre-selected target antigen. In addition, the selected target antigen was 
selectively over-expressed compared to TRAIL-receptors on the tumour cell surface, 
thereby, further optimizing tumour cell-speciﬁc binding. 
An additional advantage of antibody fragment targeted sTRAIL over conventional sTRAIL 
is its acquired capacity to activate TRAIL-R2. Conventional sTRAIL can efﬁciently activate 
TRAIL-R1 but not TRAIL-R2, the high afﬁnity receptor that is activated only by membrane-
bound TRAIL or sTRAIL secondarily crosslinked by antibodies45,46. Consequently, sTRAIL 
induces apoptosis less effectively in the many tumour types that predominantly express 
TRAIL-R2. Importantly, antibody fragment-mediated binding converts soluble scFv:sTRAIL 
into an artiﬁcial membrane bound form of TRAIL. Subsequently, a surplus of sTRAIL 
domains is available on the target cell surface for crosslinking of TRAIL-R2 on proximal 
tumour cells, resulting in enhanced target antigen-restricted reciprocal apoptosis.
Here, we report on a novel fusion protein, scFv425:sTRAIL, designed to combine EGFR-
signalling inhibition with tumour-speciﬁc apoptosis induction by sTRAIL. ScFv425:sTRAIL 
consists of an antibody fragment derived from EGFR-blocking monoclonal antibody 
MAb 42512 genetically fused to sTRAIL. Binding of scFv425:sTRAIL via the high afﬁnity 
antibody fragment leads to speciﬁc accretion to the cell surface of EGFR-positive tumour 
cells. EGFR-speciﬁc binding of scFv425:sTRAIL was designed to rapidly inhibit EGFR 
signalling and, thereby, to sensitize cells to apoptosis47. EGFR-restricted binding of 
scFv425:sTRAIL restores full signalling capacity of scFv425:sTRAIL for both TRAIL-
R1 and TRAIL-R2. Here we present a new therapeutic strategy combining EGFR-signal 
inhibition with simultaneous target antigen-restricted apoptosis induction by TRAIL. 





The following cell lines were purchased from the ATTC (Manassas, USA); Jurkat (ALL T-
cell line), A431 (epidermoid vulva carcinoma), A172, Hs683 (glioblastoma), SW948, and 
WiDr (colon carcinoma). Jurkat.EGFRvIII was generated by electroporation of Jurkat cells 
with plasmid pHβApr-1-neo/EGFRvIII (kind gift of Dr. D. Bigner, Duke University Medical 
Center, NC, USA), after which transfectants were selected by G418 selection (500 µg/ml, 
Gibco Life Technologies b.v. Breda, The Netherlands). Cell lines were cultured at 37°C, in 
a humidiﬁed 5% CO2 atmosphere. Jurkat, SW948, and WiDr were cultured in RPMI 1640 
(Cambrex Bio Science, Verviers, France) supplemented with 15% FCS. A431, HS683 and 









Monoclonal antibodies and inhibitors
TRAIL neutralizing MAb 2E5 was purchased from Alexis (10P’s, Breda, The Netherlands). 
MAb 425 (kindly provided by Merck, Darmstadt, Germany) is a murine IgG2a with high 
binding afﬁnity for the extra-cellular domain of EGFR and the mutant tumour speciﬁc 
variant EGFRvIII. MAb 425 blocks EGF binding to EGFR and competes with scFv425 for 
binding to the same epitope. Total caspase inhibitor Z-VAD-FMK, caspase-8 inhibitor Z-
IETD-FMK, and caspase-9 inhibitor Z-LEHD-FMK were purchased from Calbiochem (San 
Diego, CA, USA). EGFR tyrosine kinase inhibitor Iressa was kindly provided by AstraZeneca 
Inc (Macclesﬁeld, Cheshire, UK). PI3K inhibitor Wortmannin was purchased from Sigma-
Aldrich (Zwijndrecht, The Netherlands). Final working concentrations of inhibitors were 
diluted in serum free medium from a stock of 10 mM in DMSO.
 
Production of scFv425:sTRAIL
Fusion protein scFv425:sTRAIL was constructed and produced essentially as described 
previously43. Brieﬂy, In the ﬁrst MCS of vector pEE14, the high-afﬁnity antibody fragment 
scFv425 (Vh-(G4S)3-Vl format)48 was directionally inserted using the unique SﬁI and NotI 
restriction enzyme sites. In the second MCS, a PCR-truncated 593 bp DNA fragment encoding 
the extracellular domain of human TRAIL (sTRAIL) was cloned in frame using restriction 
enzymes XhoI and HindIII, yielding plasmid pEE14-scFv425:sTRAIL. Expression plasmid 
pEE14-scFv425:sTRAIL was transfected into CHO-K1 cells using Fugene 6 reagent (Roche 
Diagnostics, Almere, The Netherlands) according to manufacturer’s recommendations, 
after which transfectants were selected by the glutamine synthetase system as described49. 
Single cell sorting using the MoFlo high speed cell sorter (Cytomation, Fort Collins, USA) 
established clone 100F1, stably secreting 2,4 µg/ml scFv425:sTRAIL into the culture 
medium.
EGFR-speciﬁc binding of scFv425:sTRAIL 
EGFR-speciﬁc binding of scFv425:sTRAIL was assessed by ﬂow cytometry using the EGFR-
positive tumour cell line A431 and the EGFR-negative cell line Jurkat. In short, 1∙106 cells 
were incubated with scFv425:sTRAIL (300 ng/ml) in the presence or absence of MAb 
425 (3 µg/ml). Speciﬁc binding of scFv425:sTRAIL was detected using PE-conjugated 
anti-TRAIL MAb B-S23 (Diaclone SAS, Besançon, France) and subsequent FACS analysis 
using an EPICS ELITE ﬂow cytometre (Beckman Coulter, Mijdrecht, The Netherlands). 
Incubations were carried out for 45 min at 0°C and were followed by two washes with 
serum free medium.
Target cell-restricted induction of apoptosis by scFv425:sTRAIL
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of tumour cell viability, loss of mitochondrial membrane potential (∆ψ), caspase-8 and -3 
activation, and PARP cleavage/DFF degradation, as described in more detail below. Where 
indicated, treatment with scFv425:sTRAIL was performed in the presence or absence of 
MAb 425 (3 µg/ml) or MAb 2E5 (1 µg/ml).
Apoptosis assessed by viability assay
Cells were pre-cultured in a 96-well plate at a density of 3∙104 cells/well. Subsequently, 
cells were treated for 16 h with the various experimental conditions in a ﬁnal volume 
of 200 µl. Cell viability of adherent cell lines was determined by crystal violet staining 
(Sigma, Germany) as described previously44. Cell viability of suspension cell lines was 
determined using MTS assay (Promega Benelux b.v., Leiden, The Netherlands) according 
to manufacturer’s recommendations. Experimental apoptosis induction was quantiﬁed 
as the percentage of apoptosis induction compared to base-line apoptosis in medium 
control, which was set at 0% apoptosis. Each experimental condition consisted of six 
independent wells.
Apoptosis assessed by loss of Mitochondrial Membrane Potential (∆ψ)
∆ψ was analyzed using the stain DiOC6 (Eugene, The Netherlands) as previously 
described43. Brieﬂy, cells were pre-cultured in a 24-well plate at a concentration of 
0.5∙106 cells/well. Subsequently, cells were treated for 16 h with the various experimental 
conditions, after which cells were harvested and incubated for 20 minutes with DiOC6 
(0,1 µM) at 37°C, harvested (300xg; 5 min.), resuspended in PBS, and analyzed by ﬂow 
cytometry.
Immunoblot analysis
Cells were pre-cultured at 1.5∙106 cells/well in a 6-well plate, after which cells were 
incubated with scFv425:sTRAIL in the presence or absence of MAb 425 or MAb 2E5 
for the indicated time-points. Cell lysates were prepared as described previously43. 
Subsequently, 30 µg of lysate was separated by SDS-PAGE under reducing conditions and 
transferred to nitrocellulose by electro blotting. Apoptosis signalling: Caspase activation 
was detected using antibodies directed against caspase-8 and active caspase-3 (Cell 
signalling, Beverly, MA, USA). PARP cleavage and DFF degradation was assessed using 
anti-PARP MAb (Santa Cruz Biotechnology Inc., Santa Cruz, Ca, USA) and anti-DFF MAb 
(Santa Cruz). Expression of c-FLIPL and BAD phosphorylation was determined using anti-
c-FLIPL MAb clone NF6 (Alexis) and anti-phospho BAD antibody (Cell signalling). EGFR 
signalling: Expression levels of total and active EGFR were assessed using anti-total 
EGFR (Cell Signalling) and anti-activated EGFR (Tyr1173) (Santa Cruz). The different 









sampler kit (Cell Signalling) and phospho-AKT sampler kit (Cell Signalling). Equal protein 
loading was assessed using anti-actin MAb (Boehringer Mannheim, Germany). Speciﬁc 
binding was visualized using appropriate secondary HRPO-conjugated antibody (DAKO 
Cytomation, Glostrup, Denmark) and chemoluminescence (Roche).
Differential quantiﬁcation of apoptosis in target and bystander cells during mixed culture 
experiments 
Differential cell membrane labelling of target and bystander cells was achieved using 
the Vybrant Multicolor Cell-Labelling kit (Molecular probes). Brieﬂy, Jurkat.EGFRvIII 
target cells were labelled with the red ﬂuorescent dye DiI. Labelling was performed 
by incubation of Jurkat.EGFRvIII cells (1⋅106 cells/ml in serum free medium) with 
5µM DiI (37°C, 5 min), followed by three washes with standard medium. DiI-labelled 
Jurkat.EGFRvIII target and non-labelled Jurkat bystander cells were mixed at the 
indicated ratios at a ﬁnal concentration of 0.5⋅106 cells/well in a 24-well plate. After 
treatment, differential ﬂuorescent characteristics of target cells and bystander cells were 
used to separately evaluate induction of apoptosis in both populations by ∆ψ as described 
above.
Synergistic induction of apoptosis by scFv425:sTRAIL and Iressa
Jurkat.EGFRvIII cells and A431 cells were simultaneously treated with suboptimal 
concentrations of scFv425:sTRAIL (80 ng/ml) and Iressa (250 and 2000 nM, respectively), 
unless indicated otherwise. Where indicated, cells were co-incubated with MAb 425 
(3 µg/ml), MAb 2E5 (1 µg/ml), Z-VAD-FMK (1 µg/ml), Z-IETD-FMK (1 µg/ml), Z-LEHD-
FMK (1 µg/ml), or PI3K inhibitor Wortmannin (10 μM). After 16 h treatment, apoptosis 
was assessed by ∆ψ as described above. Synergy was determined using the cooperativity 
index (CI), in which the sum of apoptosis induced by single-agent treatment is divided 
by apoptosis induced by combination-treatment. When CI<1, treatment was termed 
synergistic. The effect of single-agent and co-treatment of scFv425:sTRAIL and Iressa 
on apoptotic signalling and EGFR-signal transduction by PI3K and MAPK was assessed by 
immunoblot as described above.
 
Results
EGFR-speciﬁc binding of scFv425:sTRAIL
To assess whether scFv425:sTRAIL displayed speciﬁc and enhanced binding to EGFR-
positive cells, A431 cells were incubated with scFv425:sTRAIL and analyzed for binding 
by ﬂow cytometry. Strong binding of scFv425:sTRAIL was detected to the cell surface 
(Fig.1A, solid line), which could be speciﬁcally inhibited by pre-incubation with parental 
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TRAIL-receptors on the cell surface of EGFR-negative Jurkat cells was barely detectable 
(Fig.1B). The intensity of scFv425:sTRAIL binding directly correlated to the amount of cell 
surface expressed EGFR (data not shown). 
EGFR-restricted induction of apoptosis by scFv425:sTRAIL
Treatment of EGFR-positive tumour cell lines with scFv425:sTRAIL (300 ng/ml) potently 
induced apoptosis (Fig.2A: A431; 66%, HS683; 85%, WiDr; 68%, SW948; 78%, A172; 
70%, Jurkat.EGFRvIII; 82%), whereas EGFR-negative Jurkat cells were fully resistant 
to treatment (3%). Apoptosis was speciﬁcally inhibited when cells were co-incubated 
with MAb 425 or TRAIL-neutralizing MAb 2E5 during treatment with scFv425:sTRAIL 
(Fig.2B). Binding of scFv425:sTRAIL to EGFR and subsequent reciprocal activation of 
agonistic TRAIL-receptors in a paracrine fashion should also lead to apoptotic activity 
towards neighbouring EGFR-negative tumour cells. To investigate the presence of such 
a bystander effect, Jurkat.EGFRvIII target cells were mixed with Jurkat bystander cells 
(ratio 1:1) and treated with scFv425:sTRAIL. After treatment, bystander and target cells 
were separately assessed for apoptosis, which identiﬁed a potent bystander effect of 
64% apoptosis in Jurkat bystander cells (Fig.2C). Apoptosis in Jurkat.EGFRvIII target 
cells reached approximately 50%. In both target cells and bystander cells, apoptosis was 
speciﬁcally inhibited by co-treatment with MAb 425 (4%) or MAb 2E5 (1%) (Fig.3C).
Inhibition of EGFR-signalling and subsequent sensitization to apoptosis by 
scFv425:sTRAIL treatment
Since scFv425:sTRAIL primarily binds via its EGFR-blocking antibody fragment scFv425, 
Fig.1. EGFR-speciﬁc binding of scFv425:sTRAIL. Binding of scFv425:sTRAIL was analyzed 
by ﬂow cytometry using A; the EGFR-positive cell line A431 and B; the EGFR-negative cell line 
Jurkat. Cell lines were incubated with scFv425:sTRAIL alone (solid line) and, in the case of A431, 
were additionally pre-incubated with parental EGFR-blocking MAb 425 (dashed line). Binding of 
scFv425:sTRAIL was visualized using a monoclonal PE-conjugated anti-TRAIL antibody. Fluorescent 




























the effect of scFv425:sTRAIL treatment on EGFR-signalling was determined. In A431 
cells, scFv425:sTRAIL induced a rapid dephosphorylation of EGFR at Tyr 1173 within 10 
min, while total EGFR levels remained constant (Fig.3A). The phosphorylation of EGFR 
observed during normal culture conditions is most likely due to a previously described 
TGFα-induced autophosphorylation loop50. Speciﬁc inactivation of EGFR signalling was 
















































Fig.2. EGFR-restricted induction of apoptosis by scFv425:sTRAIL A; A panel of EGFR-positive 
tumor cell lines (A431, Hs683, WiDr, SW948, A172, and Jurkat.EGFRvIII) and an EGFR-negative cell 
line (Jurkat) was treated with 300 ng/ml scFv425:sTRAIL. Apoptosis induction was analyzed after 16 
h using viability assay. B: A431 and Jurkat.EGFRvIII were treated with scFv425:sTRAIL (300 ng/ml) 
in the presence or absence of MAb 425 or TRAIL-neutralizing MAb 2E5. After 16 h, apoptosis induction 
was assessed by ∆y. C: Mixed cultures of Jurkat.EGFRvIII target cells and parental Jurkat bystander 
cells (ratio 1:1) were treated for 16 h with scFv425:sTRAIL in the presence or absence of MAb 425 
or MAb 2E5. Differential ﬂuorescent labeling of the target and bystander population was used to 
separately assess apoptosis by ∆ψ. Indicated values in bar graphs represent mean + standard error 
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Fig.3. Inhibition of EGFR signaling and sensitization to apoptosis by scFv425:sTRAIL. A431 
cells were challenged with 300 ng/ml scFv425:sTRAIL in the presence of 1 µg/ml cycloheximide for 
10 min, 1h, and 3 h. At elapsed time-point 3h, cells were additionally treated with scFv425:sTRAIL 
in the presence or absence of MAb 425 or MAb 2E5. A; Cell lysates were analyzed for the amount of 
total and phosphorylated EGFR (pTyr1173). B; Cell lysates were analyzed for MAPK and PI3K pathway 
activity by measurement of phosphorylated p44/42 MAPK, total and phosphorylated Akt. Actin levels 
were determined to conﬁrm equal protein loading. C; Cell lysates were analyzed for the apoptosis 
associated features of caspase-8 activation, the expression level of c-FLIPL and the phosphorylation 































at 1 and 3 h of treatment (Fig.2B). In addition, the PI3K pathway was markedly inhibited 
after 1 and 3 h of treatment, as measured by dephosphorylation of Akt at residues Tyr308 
and Ser473 (Fig.2B), while total Akt levels remained constant.
Resistance to apoptosis by EGFR-signalling is mediated in part by its effect on the anti-









signalling was inactivated by scFv425:sTRAIL treatment, c-FLIPL expression and BAD 
phosphorylation were investigated. At early time-points of 1 and 3 h of treatment, a 
decrease was detected in expression of the anti-apoptotic caspase 8 homologue c-FLIPL 
(Fig.3C), which coincided with the activation of caspase 8 (Fig.3C). Additionally, a marked 
decrease was observed in phosphorylation of BAD (Fig.3C), sensitizing the mitochondria 
to apoptosis.
Fig 4. Synergistic target-cell restricted apoptosis induction by scFv425:sTRAIL and Iressa. 
A; A431 cells and B; Jurkat.EGFRvIII cells were treated with increasing concentrations of the EGFR-
TKI Iressa in the presence or absence of a ﬁxed concentration of scFv425:sTRAIL (80 ng/ml). C; 
Jurkat.EGFRvIII cells and A431 cells were treated with increasing concentrations of scFv425:sTRAIL 
in the presence of a ﬁxed concentration of Iressa (250 nM and 2000 nM, respectively). D; Jurkat.
EGFRvIII, A431, and Jurkat cells were treated alone, or with a combination of scFv425:sTRAIL and 
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Synergistic induction of apoptosis by scFv425:sTRAIL and Iressa
Previously EGFR-signalling inhibition was shown to synergistically enhance TRAIL-
activity21. Therefore, potential synergistic effects of scFv425:sTRAIL with the EGFR-TKI 
Iressa was assessed on A431 cells and Jurkat cells positive for the mutant receptor 
EGFRvIII. Treatment of A431 cells with increasing concentrations of Iressa (250 - 
2000 nM) and a ﬁxed concentration of scFv425:sTRAIL (100 ng/ml) resulted in a 
dose-dependent synergistic increase in apoptosis (Fig.4A). Similar results, but with 
lower concentrations of Iressa (50 - 250 nM) and scFv425:sTRAIL (80 ng/ml), were 
obtained for Jurkat.EGFRvIII (Fig.4B). Dose-response curves of treatment with a ﬁxed 
concentration of Iressa (250 and 2000nM, respectively) and increasing concentrations of 
scFv425:sTRAIL (up to 100 ng/ml) revealed a potent dose-dependent increase in apoptosis 
in both A431 and Jurkat.EGFRvIII cells already at 20 ng/ml of scFv425:sTRAIL (Fig.4C). 
The synergistic pro-apoptotic activity of scFv425:sTRAIL and Iressa was potently inhibited 
by co-treatment with MAb 425 (Fig.4C). Target antigen-negative Jurkat cells, subjected to 
the same experimental conditions, were fully resistant to treatment (Fig.4D). In control 
experiments with DMSO, alone or in combination with scFv425:sTRAIL, no signiﬁcant 
induction of apoptosis was detected (data not shown). 
Synergistic induction of apoptosis by scFv425:sTRAIL and Iressa is caspase 8-mediated
Next, the mechanism underlying the synergistic pro-apoptotic effect was investigated. 
Treatment of A431 cells and Jurkat.EGFRvIII cells with scFv425:sTRAIL and Iressa did 
not signiﬁcantly alter TRAIL receptor expression (data not shown). Using speciﬁc caspase 
inhibitors, induction of apoptosis was found to be largely caspase-8 dependent, since the 
speciﬁc caspase-8 inhibitor Z-IETD-FMK inhibited apoptosis to levels observed for Iressa 
alone (Fig.5A). On the other hand, caspase-9 inhibition using Z-LEHD-FMK only had a 
minimal effect. Immunoblot analysis further revealed a strong activation of both caspase 8 
and 3, resulting in PARP cleavage within 3 h of treatment with scFv425:sTRAIL and Iressa 
(Fig.5B). Single agent treatment only marginally activated caspase-8 and caspase-3 
(Fig. 5B). Similar results were obtained when A431 cells were treated with scFv425:sTRAIL 
and Iressa (Fig.5C). The appearance of apoptotic features was speciﬁcally inhibited when 
treatment was performed in the presence of MAb 425 (Fig.5B and C). 
Inhibition of EGFR signalling by co-treatment with scFv425:sTRAIL and Iressa 
Simultaneous treatment of Jurkat.EGFRvIII with scFv425:sTRAIL and Iressa resulted in 
PI3K inactivation within 2 h in Jurkat.EGFRvIII, as measured by Akt dephosphorylation 
at Ser 473 (Fig.6A). No inhibition of MAPK signalling was observed in Jurkat.EGFRvIII, 
which is in line with a previous report showing that EGFRvIII speciﬁcally regulates PI3K 









signalling in Jurkat.EGFRvIII (Fig.6A). The role of PI3K inhibition in the synergistic 
pro-apoptotic effect on Jurkat.EGFRvIII was conﬁrmed by simultaneous treatment of 
Jurkat.EGFRvIII with the speciﬁc PI3K inhibitor Wortmannin and scFv425:sTRAIL, 






















































Fig.5. Synergistic induction of apoptosis by scFv425:sTRAIL and Iressa is caspase-8 
mediated. A; Jurkat.EGFRvIII cells were subjected to single agent and combination treatment with 
scFv425:sTRAIL and Iressa. Co-treatment was performed in the presence of total caspase inhibitor 
Z-VAD-FMK, caspase-8 inhibitor Z-IETD-FMK, and caspase-9 inhibitor Z-LEHD-FMK. Apoptosis was 
determined by ∆ψ after 16 h of treatment. Values indicated are mean + standard error of the mean 
of three independent experiments. B; Jurkat.EGFRvIII cells and C; A431 cells were subjected to 
single agent- and co-treatment with scFv425:sTRAIL and Iressa for 3 h, after which cell lysates were 
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(Fig.6B). For A431 cells, no effect of single agent and co-treatment was detected on 
PI3K signalling (Fig.6A). On the other hand, single agent treatment with Iressa already 

















































Fig.6. Inhibition of EGFR signaling by co-treatment with scFv425:sTRAIL and Iressa. 
Jurkat.EGFRvIII and A431 cells were treated either alone or with a combination of scFv425:sTRAIL 
and Iressa, in the presence or absence of MAb 425. After 2h treatment, PI3K pathway and MAPK 
pathway activity in A; Jurkat.EGFRvIII and B; A431 was assessed by immunoblot analysis of total 
Akt and active phosphorylated Akt, and phosphorylated MAPK, respectively. Equal protein loading 
was conﬁrmed by actin staining. C; Jurkat.EGFRvIII was treated with scFv425:sTRAIL and either 
Iressa or the speciﬁc PI3K inhibitor Wortmannin, after which apoptosis induction was assessed by ∆ψ. 
D; Cell lysates of A431 and Jurkat.EGFRvIII, treated alone or with a combination of scFv425:sTRAIL 











































































minimal effect. Co-treatment of A431 also inhibited MAPK signalling, but to a similar 
extent as Iressa treatment alone (Fig.6B).
Treatment with scFv425:sTRAIL and Iressa induces c-FLIPL down regulation
Simultaneous treatment with scFv425:sTRAIL and Iressa markedly reduced the expression 
of c-FLIPL in both Jurkat.EGFRvIII and A431 cells (Fig.6D). To a lesser extent, treatment 
with Iressa alone down-regulated c-FLIPL in A431 cells, whereas in Jurkat.EGFRvIII 
no effect of single agent treatment was seen. Treatment in the presence of MAb 425 
prevented down regulation of c-FLIPL in both cell lines.
 
Discussion
EGFR-signalling inhibition by EGFR-blocking monoclonal antibodies and small molecule 
tyrosine kinase inhibitors is a promising therapeutic approach that can restore the 
susceptibility of tumour cells to apoptosis induction. Here we describe a novel therapeutic 
approach in which EGFR-signalling inhibition is combined with target cell-restricted 
apoptosis induction using the new fusion protein scFv425:sTRAIL. Fusion protein scFv425:
sTRAIL, comprising EGFR-blocking antibody fragment scFv425 genetically fused to 
sTRAIL, clearly  accreted at the cell surface of EGFR-positive cells, which was speciﬁcally 
abrogated by pre-incubation with parental EGFR-blocking MAb 425. Together with the 
barely detectable binding of scFv425:sTRAIL to cognate TRAIL receptors on EGFR-
negative cells, these data provide strong evidence for the enhanced binding speciﬁcity of 
scFv425:sTRAIL for EGFR-positive tumour cells. 
Interestingly, high concentrations of parental MAb 425 were required to competitively 
inhibit binding of scFv425:sTRAIL, implying a high afﬁnity of scFv425:sTRAIL for EGFR. 
Previously, we demonstrated that eukaryotically expressed scFv:sTRAIL is produced as 
a soluble homogeneous trimer43. Although not investigated here, such a stable trimeric 
form would provide a logic explanation for the strong binding observed on A431 cells. 
Trimeric scFv425:sTRAIL contains three identical antibody fragment domains and 
will, therefore, beneﬁt from an associated enhanced avidity effect. Enhanced avidity 
has been shown to improve the in vivo tumour-targeting efﬁcacy in several antibody-
based strategies52,53. The above-described enhanced binding speciﬁcity and avidity of 
scFv425:sTRAIL may help increase tumour cell retention and reduce the total dose 
required to obtain a therapeutic effect.
Treatment with scFv425:sTRAIL potently induced apoptosis in EGFR-positive tumour cells 
that was speciﬁcally abrogated by co-incubation with parental MAb 425. When combined 
with the absence of apoptotic activity on EGFR-negative Jurkat cells, this established 
EGFR-speciﬁc binding of scFv425:sTRAIL as a critical component of its apoptotic activity. 
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preceded by the speciﬁc dephosphorylation of EGFR, and coincided with dephosphorylation 
of the PI3K signal transduction pathway and to a lesser extent the MAPK signal transduction 
pathway. 
This rapid inactivation of EGFR-signalling clearly points to a role for EGFR inhibition in 
scFv425:sTRAIL-induced apoptosis. One of the main regulators of TRAIL sensitivity, 
the anti-apoptotic caspase-8 homologue c-FLIPL
54-56, has previously been shown to 
be regulated by PI3K signalling57,58. In A431 cells, inactivation of PI3K signalling was 
accompanied by a decrease in expression of c-FLIPL after 1 and 3 h of treatment. Besides 
regulating c-FLIPL expression, PI3K signalling also inﬂuences the phosphorylation status 
of BAD59,60. In A431 cells, a marked dephosphorylation of BAD was detected after 1 and 
3 h. Therefore, inhibition of PI3K signalling appears to facilitate caspase 8 activation, by 
down-regulating c-FLIPL, and sensitizes the mitochondria to induction of apoptosis, by 
dephosphorylation of BAD. 
In addition to PI3K inhibition, dephosphorylation of the MAPK signal transduction pathway 
was detected after 1 and 3 h of treatment with scFv425:sTRAIL. Previously, MAPK activation 
was shown to protect against TRAIL-induced apoptosis by a mechanism occurring at or 
above the level of caspase-8 processing, which did not involve c-FLIPL
47. Conversely, 
although not formally proven here, MAPK inhibition could sensitize tumour cells towards 
scFv425:sTRAIL-induced apoptosis at or above the level of caspase 8 processing.
From the above-discussed data, a model for the apoptotic activity of scFv425:sTRAIL can 
be formulated (for schematic representation see Fig.7). First, binding of scFv425:sTRAIL 
leads to accretion at the cell surface of EGFR-positive tumour cells only. Subsequently, 
EGFR-speciﬁc binding inhibits EGFR mitogenic signalling via PI3K and MAPK and, 
thereby, sensitizes tumour cells to apoptosis by e.g. down-regulation of c-FLIPL and BAD 
dephosphorylation. Concomitantly, membrane-bound scFv425:sTRAIL induces apoptosis 
by reciprocal crosslinking of agonistic TRAIL-receptors on neighbouring EGFR-positive 
tumour cells. 
Paracrine activation of TRAIL-receptors by scFv425:sTRAIL is not necessarily restricted 
to EGFR-positive tumour cells but can also be directed towards neighbouring tumour 
cells devoid of target antigen. In a recent report, we described a potent anti-tumour 
bystander effect for an scFv:sTRAIL fusion protein with speciﬁcity for the carcinoma-
associated cell surface target antigen EGP261. Here, we show that scFv425:sTRAIL 
also potently induced apoptosis in EGFR-negative bystander Jurkat cells during mixed 
culture experiments with Jurkat.EGFRvIII cells. This pro-apoptotic bystander effect might 
help reduce the appearance of therapy-resistant recurrences emerging after seemingly 
successful treatment, as has been reported for conventional MAb-based therapy62,63. 
In a recent report, the synergistic effect of combined EGFR-targeting with the anti-









Iressa was described64. Together with the fact that TRAIL has been shown to synergize 
with anti-EGFR agents20, this provided a strong rationale for the combination of 
scFv425:sTRAIL treatment with Iressa. Potent synergistic induction of apoptosis was 
observed in both wild-type EGFR-positive A431 cells and EGFRvIII-positive Jurkat.EGFRvIII 
cells upon treatment with scFv425:sTRAIL and the Iressa. The synergistic pro-apoptotic 
effect of scFv425:sTRAIL and Iressa was fully EGFR-restricted and TRAIL-mediated and did 
not involve modulation of TRAIL receptor expression. Interestingly, inhibition of caspase 8 
activity, by a speciﬁc caspase 8 inhibitor, reduced apoptosis induction by scFv425:sTRAIL 
and Iressa to the levels observed during Iressa treatment alone. On the other hand, 
caspase 9 inhibition only had a minimal effect on apoptosis induction. These data point to 
an increased processing of caspase 8 as the main cause for the synergistic pro-apoptotic 
effect with no or only minimal involvement of the mitochondrial route of apoptosis. 
When cells were subsequently analyzed for expression of c-FLIPL, the expression level 
of which is an important regulator of caspase 8 processing, a marked down regulation 
in both Jurkat.EGFRvIII and A431 was observed within 3 h of combination treatment 
with scFv425:sTRAIL and Iressa. Down-regulation of c-FLIPL coincided with the time of 
caspase-8 activation and was preceded by inactivation of the PI3K pathway in Jurkat.
EGFRvIII cells. In A431 cells, combination treatment signiﬁcantly inhibited MAPK-
signalling but only to a similar degree as that observed during Iressa treatment alone. 
Fig 7. Schematic model of the apoptotic activity of scFv425:sTRAIL. Antibody fragment binding 
of scFv425:sTRAIL to EGFR inhibits mitogenic signaling by this receptor and its downstream signaling 
pathways and, thereby, sensitizes tumor cells to apoptosis. Furthermore, antibody fragment binding 
to EGFR immobilizes soluble scFv425:sTRAIL on the cell surface of EGFR-positive tumor cells and 
converts soluble scFv425:sTRAIL into a membrane bound form that can efﬁciently initiate apoptosis 
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Based on these results, it can be concluded that the synergistic pro-apoptotic effect 
largely depends on the speciﬁc down-regulation of c-FLIPL. For EGFRvIII positive Jurkat 
cells, down-regulation of c-FLIPL is a consequence of PI3K inhibition. In A431 cells, MAPK 
dephosphorylation may play a role but the exact mechanism remains to be elucidated.
In conclusion, we report for the ﬁrst time on a recombinant fusion protein that combines 
the tumoricidal effect of EGFR-signal inhibition with target cell-restricted apoptosis 
induction. The unique characteristics of scFv425:sTRAIL described here indicate its 
potential therapeutic value, alone and in combination with EGFR tyrosine kinase inhibitor 
Iressa, for the treatment of EGFR and EGFRvIII expressing human cancers.
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